statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Bristol-Myers Squibb Co jumped over 8% on Friday after the firm topped second quarter analyst estimates on multiple counts. The pharma giant reported Q2 revenue at $12.20 billion, which came in higher than a Street estimate of $1.63 billion.Adjusted earnings per share (EPS) came in at $2.07 as compared to an expected loss of $1.63. Following the announcement, retail sentiment flipped into the extremely bullish territory (90/100) hitting a one-year high supported by extremely high message volume (93/100).<figure class="image"><a href="https://stocktwits.com/symbol/BMY"><img style="aspect-ratio:1594/438;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_26_at_11_39_11_AM_e2726d6c4a.png" alt="Retail sentiment trends in the extremely bullish territory for Bristol-Myers Squibb" width="1594" height="438"></a><figcaption>Retail sentiment trends in the extremely bullish territory for Bristol-Myers Squibb</figcaption></figure>During the second quarter, revenue rose 9% year-over-year (YoY) while EPS witnessed a growth of 18% YoY. The revenue was driven by the firm’s Growth Portfolio and its drug Eliquis.US revenues increased 13% to $8.80 billion, primarily due to the growth and legacy portfolios while international revenues fell 1% to $3.40 billion, primarily due to the negative impact from foreign exchange of 7% and Revlimid.As far as product revenues are concerned, the firm’s Growth Portfolio worldwide revenues increased 18% to $5.60 billion, primarily driven by higher demand for Opdivo, Reblozyl, Camzyos and Opdualag. Revenues for the Legacy Portfolio in the second quarter grew 2% to $6.60 billion, driven by higher demand for Eliquis and Pomalyst.The firm has raised its full-year guidance, now expecting total revenues in the upper end of low-single digit range compared to low single-digit increase it guided in April. Diluted EPS was ratcheted up to $0.60-$0.90 from an earlier guidance of $0.40-$0.70.Christopher Boerner, board chair and chief executive officer at Bristol-Myers Squibb said as the firm moves into the second half of the year, it remains focused on prioritizing opportunities with the greatest growth potential and impact for patients, including the anticipated U.S. launch of KarXT. &nbsp;Meanwhile, retail investors are viewing this as a potential turning point for the stock. One Stocktwits user named ‘Namhguab’ believed the stock was undervalued near the $42 level and still sees further upside following today’s news.<figure class="image"><a href="https://stocktwits.com/Namhguab/message/580799100"><img style="aspect-ratio:1542/356;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_07_26_at_11_40_21_AM_fcf9d0f598.png" alt="Stocktwits user Namhguab's post on Bristol-Myers Squibb" width="1542" height="356"></a><figcaption>Stocktwits user Namhguab's post on Bristol-Myers Squibb</figcaption></figure>Photo Courtesy: Bristol-Myers Squibb

Bristol Myers Earnings Beat: Retail Sentiment Hits One-Year High

Shares of Bristol-Myers Squibb Co jumped over 8% on Friday after the firm topped second quarter analyst estimates on multiple counts. The pharma giant reported Q2 revenue at $12.20 billion, which came in higher than a Street estimate of $1.63 billion.

Shares of Bristol-Myers Squibb Co jumped over 8% 

Equity

The biopharma company’s adjusted earnings per share (EPS) came in at $2.07 as compared to an expected loss of $1.63. Following the announcement, retail sentiment flipped into the extremely bullish territory (90/100) hitting a one-year high.

Is Schwab US Dividend Equity ETF the Best Dividend ETF for You?

Is Schwab US Dividend Equity ETF the Best Dividend ETF for You...

Schwab US Dividend Equity ETF  (SCHD, $80.14) RSI Indicator left the overbought zone on April 01, 2024

This is a signal that SCHD's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Schwab US Dividend Equity ETF  (SCHD, $80.63) RSI Indicator left the overbought zone on March 28, 2024

Schwab US Dividend Equity ETF  (SCHD, $79.38) RSI Indicator left the overbought zone on March 22, 2024

Schwab US Dividend Equity ETF  (SCHD, $79.24) RSI Indicator left the overbought zone on March 20, 2024

Schwab US Dividend Equity ETF  (SCHD, $78.83) RSI Indicator left the overbought zone on March 14, 2024

Schwab US Dividend Equity ETF  (SCHD, $79.26) RSI Indicator left the overbought zone on March 13, 2024

Dream ETF portfolio: MOAT, IBIT, SCHD, COWZ and QQQ

Exchange-Traded Funds (ETFs) are some of the best assets to invest in, especially for long-term investors. These funds offer diversification, often at a low cost. According to YCharts, there are now...

SCHD is a great dividend ETF: Buy these other funds too

The Schwab US Dividend Equity ETF (SCHD) is one of the most popular dividend funds in Wall Street with over $52 billion. This popularity is for a good reason as it has a long track record of beating...

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Volume	2.5M
52-Wk High	$82.94
52-Wk Low	$66.67

SCHD Schwab US Dividend Equity ETF

About

Feed

News

Sentiment

Fundamentals